These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9093386)

  • 21. [Molybdocene dichloride as an antitumor agent (author's transl)].
    Köpf-Maier P; Leitner M; Voigtländer R; Köpf H
    Z Naturforsch C Biosci; 1979 Dec; 34(12):1174-6. PubMed ID: 161840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of glycyrrhizin on the evolution and respiration of Ehrlich ascites tumour cells.
    Rossi T; Galatulas I; Bossa R; Tampieri A; Tartoni P; Baggio G; Ruberto AI; Castelli M
    In Vivo; 1995; 9(3):183-6. PubMed ID: 8562878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gossypol inhibits Ehrlich ascites tumor cell proliferation.
    Tso WW
    Cancer Lett; 1984 Oct; 24(3):257-61. PubMed ID: 6498805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the genotoxic, cytotoxic, and antitumor properties of Commiphora molmol using normal and Ehrlich ascites carcinoma cell-bearing Swiss albino mice.
    Qureshi S; al-Harbi MM; Ahmed MM; Raza M; Giangreco AB; Shah AH
    Cancer Chemother Pharmacol; 1993; 33(2):130-8. PubMed ID: 8261571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organ toxicity of metallocene dichlorides. The effect of (C5H5)2TiCl2 and (C5H5)2VCl2 on renal structure.
    Köpf-Maier P; Funke-Kaiser P
    Toxicology; 1986 Jan; 38(1):81-90. PubMed ID: 3942012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of necroses, virus activation and giant cell formation after treatment of Ehrlich ascites tumor with metallocene dichlorides.
    Köpf-Maier P
    J Cancer Res Clin Oncol; 1982; 103(2):145-64. PubMed ID: 7096436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice.
    Knežević AH; Dikić D; Lisičić D; Kopjar N; Oršolić N; Karabeg S; Benković V
    Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):343-9. PubMed ID: 21624058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergism between propolis and hyperthermal intraperitoneal chemotherapy with cisplatin on ehrlich ascites tumor in mice.
    Oršolić N; Car N; Lisičić D; Benković V; Knežević AH; Dikić D; Petrik J
    J Pharm Sci; 2013 Dec; 102(12):4395-405. PubMed ID: 24136132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan.
    Oršolić N; Benković V; Lisičić D; Dikić D; Erhardt J; Knežević AH
    Med Oncol; 2010 Dec; 27(4):1346-58. PubMed ID: 20013318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antitumor effect of intraperitoneal treatment with rhTNF-alpha muteins on Ehrlich ascites tumor growth.
    Terlikowski S; Nowak HF
    Cancer Biother Radiopharm; 2000 Feb; 15(1):39-46. PubMed ID: 10740651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimitotic activity of the methylhydrazine derivative Natulan in the ehrlich ascites carcinoma; dose-effect relationship.
    Llombart A; Mínguez FP
    Oncology; 1969; 23(3):201-8. PubMed ID: 5785067
    [No Abstract]   [Full Text] [Related]  

  • 32. Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom.
    de Vieira Santos MM; da Silva RJ; da Silva MG; Fecchio D
    Mediators Inflamm; 2004 Feb; 13(1):29-32. PubMed ID: 15203562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of L- and D-lysine on the growth of Ehrlich ascites tumour.
    Choy YM; Fung KP
    Chemotherapy; 1989; 35(2):119-22. PubMed ID: 2503300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-proliferative activity and mechanism of action of titanocene dichloride.
    Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
    Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Method for an increase of the number of anaphases in Ehrlich ascites tumour cells in mouse.
    Bogajewski J
    Acta Anthropogenet; 1983; 7(4):331-49. PubMed ID: 6680313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the effect of polyamines and their products on Ehrlich ascites tumours.
    Mondovì B; Gerosa P; Cavaliere R
    Agents Actions; 1982 Oct; 12(4):450-1. PubMed ID: 6817619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A method to score micronuclei in vivo using cytochalasin B-induced cytokinesis block.
    Uma Devi P; Satish Rao BS; Kamath R
    Mutat Res; 1998 Jun; 401(1-2):33-7. PubMed ID: 9639669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wild-type and cultured Ehrlich ascites tumour cells differ in tumorigenicity, lectin binding patterns and binding to basement membranes.
    Knibbs RN; MacCallum DK; Lillie JH; Goldstein IJ
    Glycobiology; 1994 Aug; 4(4):419-28. PubMed ID: 7827403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor organometallics. I. Activity of some diphenyltin(IV) and diphenylantimony(III) derivatives on in vitro and in vivo Ehrlich ascites tumor.
    Bara A; Socaciu C; Silvestru C; Haiduc I
    Anticancer Res; 1991; 11(4):1651-5. PubMed ID: 1836124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of various new cytostatic agents on DNA reduplication and proliferation kinetics in the Ehrlich-Lettre ascites tumor model].
    Andreeff M
    Verh Dtsch Ges Inn Med; 1974; 80():1678-80. PubMed ID: 4454511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.